Some COVID Patients Recover Quickly, Have Better Immunity, Study Finds
FRIDAY, Nov. 6, 2020 -- Certain COVID-19 patients not only recover faster from the coronavirus, but their bodies also show longer-lasting immunity, according to a new study.
"We've found a subset of individuals that heal quickly while sustaining virus-specific antibody levels after COVID-19," said Dr. Duane Wesemann. He's an associate physician at Brigham and Women's Hospital in Boston and an associate professor at Harvard Medical School.
"The kind of immune response we're seeing in these individuals is a bit like investing in an insurance policy -- it's the immune system's way of adding a potential layer of protection against future encounters with the virus," the immunologist said in a hospital news release.
For the study, the researchers collected blood samples monthly from 92 people in the Boston area who had recovered from mild to moderate bouts of the coronavirus between March and June 2020.
The team analyzed the blood samples, measuring a range of antibodies against the virus, including immunoglobulin-G (IgG). The investigators split the group into two categories, depending on whether the participants sustained their antibody levels for several weeks or lost them. Most lost their IgG levels within three to four months, the findings showed, but 20% had antibody production that was stable or even enhanced over that time.
The researchers learned that the "sustainers" had symptoms for an average of 10 days, and also had differences in two types of immune cells (memory T cells and B cells) that play a key role in immune memory and protection, compared to those whose antibodies decayed. The "decayers" had virus symptoms for an average of 16 days.
"The data point to a type of immune response that's not only adept at handling viral disease by leading to a swift resolution of symptoms, but also better at producing cells that can commit to longer-term production of antivirus IgG antibodies," Wesemann said.
"Figuring out how these individuals are able to support longer-term antibody production is relevant to COVID-19, and will also have important implications for our understanding of the immune system in general," he added.
The results were published online Nov. 3 in Cell.
© 2021 HealthDay. All rights reserved.
Posted: November 2020
Further Support and Information on COVID-19
Read this next
WEDNESDAY, Jan. 27, 2021 -- Retired doctors and nurses are being called to the front lines of the U.S. coronavirus vaccination effort, the White House COVID-19 Response team...
WEDNESDAY, Jan. 27, 2021 -- New and more infectious coronavirus variants are beginning to appear in the United States, but all have remained vulnerable to the two vaccines now...
WEDNESDAY, Jan. 27, 2021 -- To the ever-growing list of COVID-19's collateral damage, add one more casualty: cancer research. A new study indicates that during the first...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.